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1. Introduction 
In contrast to renal or pancreas transplantation graft failure after heart transplantation (HTx) is 
associated with the death of the patient if re-grafting or mechanical support (MCS) is not 
possible immediately. Since the beginning of modern transplantation medicine one of the 
highest priorities were preventing and treating graft rejection. Over the last decades 
experimental, animal and clinical research resulted in the development of new 
immunosuppressive (IS) drugs leading to an improved patient and graft survival. The efforts 
of transplant professions to develop new IS protocols trying to reduce the toxic side effects, 
resulted in an improvement of quality of life (QoL) for transplant recipients.  
2. Historical consideration  
At the beginning of the twentieth century research work by Alexis Carrel on performing 
surgical anastomosis [1, 2] allowed organ revascularization and marked one of the pre-
conditions for organ transplantation. It was the Stanford group of Lower and Shumway 
who first started to study the problems of HTx [3-5] leading to the first human HTx by 
Banard in 1967 [6]. Within the next year over 100 HTx were done worldwide. Even if 
technical successful the great enthusiasm for this new therapy decreased rapidly when the 
poor survival rate became obvious [7]. One of the biggest problem was preventing and 
controlling graft rejection. Corticosteroides and Azathioprine (AzA) were the main drugs 
used for IS at that time. The Standford group added rabbit antithymocyte globulin (ATG) to 
the protocol gaining acceptable survival rates [8]. The main breakthrough came a decade 
later with a drug called Cyclosporine (CsA). The great advantage of CsA was the selective 
immunoregulation of T cells in contrast to the non-selective inhibition of cell proliferation by 
AzA and corticosteroids. CsA was first used in clinical organ transplantation in 1978 [9] and 
in 1983 it was approved for clinical use to prevent graft rejection in transplantation. Today 
transplant professions throughout the world contribute the great success of HTx to the 
introduction of CsA into clinical practice. Four years after the first use of CsA Kino reported 
of a new IS agent even more potent compared to CsA called FK 506 [10]. It was Starzl and 
the Pittsburgh Group who but much effort in the establishment of FK 506 into IS protocols 
[11]. In the recent FK 506 is more frequently used compared to CsA [12].  
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As early as 1896, mycophenolate acid (MPA), the activated form of mycophenolate mofetil 
(MMF) was extracted from Penicillium stoloniferum (Gosio, B. 1896. Ricerche batteriologiche 
chimiche sulle alterazioni del mais. Riv. Igiene Sanita Pub. Ann.7:825-869. 16. Jaureguiberry). 
The cytostatic effect was reported by Brewin in 1972 and was first used in the treatment of 
neoplasia [13]. The first report of MMF use as IS drug in animal research was in a heterotopic 
HTx model in rats [14].   
Lately a new category named proliferation signal inhibitors (PSI), including Rapamycin 
(Rapa) and Everolimus (EvE) have been introduced to clinical practice. Rapa was discovered 
in 1965 but it took years before it was introduced to transplantation medicine. The research 
work of Rapa led to the discovery of the action of the mammalian target of Rapamycin 
(mTOR).  
3. Immunosuppressive regimes and agents  
Starting with the exploration of CsA the field of IS agents has evolved drastically resulting 
in the possibility of more combinations for different indications. All IS agents have a narrow 
therapeutic window in common. Transplant physicians have to find an optimal balance 
avoiding allograft rejection and avoid toxic side effects. There are mainly three categories for 
IS therapy: first its use as induction therapy, second to maintain the organ allograft 
(maintenance therapy) and finally if needed to treat acute rejection episodes (anti-rejection 
therapy). In the following we focus on the recent used IS agents, acting at T cell mediated 
processes of rejection. Further agents focusing on the role of antibody mediated rejection 
may be found in the next chapter.  
The highest number of rejection episodes will be within the first months after HTx; therefore 
up to 50% HTx centres worldwide are using a protocol with high IS for the early post-
operative period (=Induction therapy or augmented IS therapy) [12].  
Interactions of IS drugs and other medications may be extensively and categorised in minor, 
moderate and major interactions. Here only the most important and major interactions will 
be mentioned.  
3.1 Polyclonal antibodies 
Polyclonal Antibodies are derived mainly from rabbits or horses, after the animals have 
been immunized with human lymphocytes (ALS) or thymocytes (ATG). Polyclonal 
antibodies have multiple distinct antigen-combining sites resulting in the depletion of 
circulating T-cells, apoptosis of activated T cells and modulation of cell surface receptor 
molecules. The IS potential of heterologous antibodies has been demonstrated early [15] and 
the first clinical use of an antilymphocyte glogulin (ALG) is reported by Starzel in 1967 [16]. 
The heavily contamination with anti-red cells and anti-platelet antibodies was resolved by 
the use of human thymocytes as the antigen source, resulting in antithymocyte globulin 
(ATG). First studied in renal transplantation, ATG was established as fix part in the Stanford 
protocol for HTx [8]. They used rabbit ATG intramusculary for the first three days after HTx 
and then every other day. The goal was a reduction of T cells to less than 5% in peripheral 
blood sample.  
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Polyclonal Antibodies have strong IS effect but its use is limited by the production of 
human antibodies against the xenogeny protein fraction allowing only a short term of use. 
This also explains the need for corticosteroids and the use of histamine antagonist therapy 
to reduce the rates of anaphylactic shock. Antipyretic medication should be added when 
ATG/ALS is given as fever and shivering are some of the prominent side effects. Further 
side effects are thrombocytopenia, leucocytopenia and anemia due to antibody cross 
reactions. The rate of opportunistic infections might be as high as 30%. It should be 
administered intravenously using a dialysis catheter or a central venous access. When 
administered intravenously using a peripheral vein, phlebitis may result and when given 
intramuscular local painful swelling leading to an abcess can occur. The goals of use of 
ATG/ALS in modern IS protocols are: Reducing or even avoiding CNIs due to their 
nephrotoxic side effects for the first days after HTx establishing a CNI free induction 
therapy, avoiding under-immunosuppression in the first postoperative days and treating 
acute cellular rejections when other regimes fail. Monitoring of polyclonal antibody 
treatment is difficult as the effectiveness might vary from charge to charge. Monitoring 
was done by achieving leucopenia later followed by using the rosette test [18]; nowadays 
the fluorescence activated cell sorter (FACS) analyses and T cell counts may be used. Most 
centres use a fixe dose regime.  
3.2 Anti-Interleuckin 2 receptor antibodies 
Agents who specific block the interleukin 2 (IL-2) receptor on activated T-cells, were 
developed to be more effective compared to non-selective polyclonal or monoclonal 
antibodies. An activated IL-2 receptor leads to rapid T cells proliferation and finally to the 
activation of B cells resulting in the production of antibodies against the allograft. The IL-2 
receptor consists of three transmembrane protein chains: ┙ (CD25), ┚ (CD122), and ┛ 
(CD132). Basiliximab (trade name Simulect) and daclizumab (trade name Zenapax) are 
humanized antibodies produced by recombinant DNA technology; both composite of about 
human (90%) and murine (10%) antibody sequences. They are derivate from non-human 
species and are monoclonal antibodies to the alpha (CD 25) subunit of the IL-2 receptor. The 
subunit where the IL-2 receptor blocker binds to is only expressed on activated but not on 
resting lymphocytes. Both drugs were first used in renal transplantation and are now 
increasingly used in HTx recipients either as induction therapy or for the treatment of graft 
rejection. FDA approval for dacluzimab was in 1997 and for basiliximab in 1998. Both drugs 
are given intravenously and should be given within 2 to 24 hours after transplantation. 
Repetition should be done within 4 days (basiliximab) or 2 weeks (daclizumab). Due to the 
different half life time of the agents: 7.2 days for basiliximab and 20 days for daclizumab. 
Serum levels may be measured by ELISA and are recommended for basiliximab 0.2 ug/ml 
(about 20mg two times in four days) and for daclizumab 5 to 10 ug/ml to achieve a proper 
saturation of the receptors. When given 2.5 to 25 mg of basiliximab twice (day 0 and 4) 
approximately 90% of available IL-2 receptors on T lymphocytes are blocked. Saturation 
maintained with basiliximab for 4 to 6 weeks, with daclizumab for about 90 to 120 days. It 
was shown that anti-IL-2 receptor antibodies when combined with standard triple druge 
regime for induction therapy compared to placebo reduces rejection episodes [19, 20]. In a 
trial using daclizumab 1 mg per kg within 24 hours after HTx and repeated every two weeks 
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for a total dosage of five, less rejection rates compared to placebo were seen [19]. In a later 
study it was shown that two doses of daclizumab are similar effective in preventing 
rejection as five doses, with no negative effects on patient survival [21]. Specific blockade of 
IL-2 receptor may prevent rejection without inducing global immunosuppression; but even 
if in the initial studies no increased opportunistic infections rates were observed alike to all 
IS agents increased risk of infection is still present. Similar to polyclonal antibodies allergic 
reactions are serious side effects. Anti-IL-2 receptor antibodies are only part of a multiple 
drug regime. There is a higher risk of lymphoma. Other side effects like nausea, vomiting, 
diarrhea, tremor, insomnia, headache, tremors, flu symptoms or swelling of peripheral 
tissue have been reported. A cytocine release syndrome has been reported as well. If anti-
IL-2 receptor antibodies are as effective as polyclonal antibodies is still controversial [22, 
23]. 
3.3 Calcineurin inhibitors 
Calcineurin (CN) is an enzyme dephosphorylating the nuclear factor of activated T-cells 
complex (NF-ATC) which is in charge for the transcription promotor of Interleukin 2 (IL-2) 
production. CN is activated when an antigen-presenting cell interacts with a T cell receptor 
leading to an up-regulation of IL-2 production. IL-2 itself activates T-helper lymphocytes 
and stimulates the production of cytokines [24]. It is discussed that the absolute amount of 
produced IL-2 influences the extent of the immune system. Drugs blocking CN are named 
Calcineurin Inhibitors (CNIs); Cyclosporine A (CsA) and Tacrolimus (TAC) are the most 
prominent agents out of this group. For all CNIs nephrotoxic and neurologic side effects are 
an issue and dose reduction or even avoidance of CNIs in HTx protocols have been studied 
extensively. Nevertheless CNIs are still a major part of IS therapy after HTx. 
3.3.1 Cyclosporine A 
Cyclosporine A (CsA) is a lipophil, cyclic polypeptide consisting of 11 amino acids. It binds 
to cyclophylin (CpN), forming a complex which blocks C, resulting it, resulting in a 
suppression of activated T-cells and B-cell function. In 1971 CsA was isolated from the 
fungus Tolypocladium inflatum, found at the Hardanger Vidda in Norway. It was first 
investigated as anti-fungal antibiotic but the antibiotic spectrum was too narrow for clinical 
use. Its immunosuppressive activity found in 1972 was first reported in 1976 by Borel [25]. 
Thereafter the effectiveness in animal and human studies was investigated by Calne and his 
group in Cambridge [26]. They soon discovered that CsA improved heterogenic heart 
allografts in rats [27]. The effectiveness of CsA was confirmed in human studies in the filed 
of renal transplantation reported by Calne [28, 29]. These studies already recognizing the 
disadvantages of CsA, like the high rate of lymphoma [28] and its nephrotoxic side effects 
[30, 31]. It was the Stanford group who introduced CsA into clinical practice for HTx [17]. 
After animal research with heterotopic and orthotopic HTx in monkey, they introduced CsA 
to 66 patients and achieved a one year survival of 80%. At that time the starting dose of CsA 
was 18mg/kg per day combined with AzA and corticosteroids. European countries 
followed this protocol [32, 33]. Today when starting CsA recommended dosages are: 
intravenously (i.v.) application: either 2 to 4 mg/kg once a day continuous over 24 hours or 
over 4 to 6 hours, 1 to 2 mg/kg twice a day over 4 to 6 hours; oral application: 8 to 12 
www.intechopen.com
 
Immunosuppressive Therapy After Cardiac Transplantation 
 
7 
mg/kg/day in 2 divided doses is common. Afterwards dosage is adjusted to target trough 
levels and dosage reduction is aimed as low as 3 to 5 mg/kg/day.  
When CsA is given per oral it is resorbed in the upper intestinal tract 30 to 60 minutes after 
the drug intake. The resorption is influenced by ingestion especially by grapefruit juice. The 
resoprtion half time is about 60 minutes. CsA is metabolized by the p450-3A enzyme in the 
intestinal wall epithelium. After passing the portal blood stream only 30% of the original 
CsA suspension will be in the systemic blood stream. The first commercially available oral 
formulation was very variable on absorption and blood concentration and it was tried to 
overcome this effect [34]. At the beginning of the 1990ies a new Cyclosporine microemulsion 
(Sandimmun Neoral, Novartis, Basel, Switzerland) was developed, resulting in a higher 
bioavailability and reducing the individual deviation attributed to ingestion. The new 
suspension reaches the maximum blood concentration after 1.5 to 2 hours [35, 36]. CsA is 
lipophil and the highest concentrations are found in the adipose tissue and in the liver. It is 
eliminated with a mean half time of 6 to 8 hours mainly across the liver, only 6% across the 
kidney. Elimination half time in children and lower in women or patients with chronic liver 
disease [37].  
When CsA was introduced to clinical practice the rejection monitoring and drug 
monitoring was at its beginning. Clinical practice rejection monitoring was done by series 
of ECG to see voltage drops. Drug monitoring was done by the toxic side effect of AzA, 
monitoring the absolute T-cell number to see a severe depression. None of these methods 
were practicable for CsA monitoring as it is not affecting the T cell count. It became clear 
that a better monitoring of drug availability and a better monitoring of rejection episodes 
are necessary. The introduction of endomyocardial biopsy (EMB) made histologic 
examination possible [38]. CsA treatment and rejection monitoring with EMB resulted in a 
significant reduction of rejection episodes but incidence of malignant lymphoma and 
early renal dysfunction increased drastically [17, 28, 29, 39]. Measurement of CsA 
concentration in the blood stream was initiated; at first hindered as there are over 20 
metabolits of CsA and the concentration itself in the blood stream is low. Today tow 
different methods are used for CsA measurement: In clinical practice the immunoassay 
(IA) is the most practicable. Different IAs have been introduced, like the 
radioimmunoassy, enzyme-multiplied immunoassay and florescence-polarisations 
immunoassay; all are using antibodies to CsA. The more specific method is the high-
performance liquid chromatography (HPLC) which may be combined with mass 
spectrometry (MS). Measuring CsA concentration may be done before the patient takes 
the drug (pre-dose level, C0 measrument) or 2 hours after the intake of the drug (C2 
measurement, 2 hours post dose). The C0 level is the more frequent and commonly used 
measurement but the C2 shows better correlation with the area under the curve and acute 
rejection episodes. A better prediction of long-term graft survival by C2 measurement was 
reported as well [40].  
Finding the optimal dose and blood level for CsA treatment was and is still a challenge. The 
The initial Stanford protocol included ATG, corticosteroids and CsA with an initial dose of 
18mg/kg followed by 10mg/kg per day [7]. The protocol was modified and CsA was 
adapted to the measurements of CsA blood trough levels, using a target area of 100 to 300 
ng/ml, followed by a further decrease to 100 to 300 ng/ml for the first month and then 
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lowered to 50 to 150 ng/ml in combination with AzA and ATG (for the first 7 days after 
HTx). This trend of avoiding high dosage of CsA to reduce the incidence of lymphoma and 
avoid CNI-induced nephrotoxicity has not ended yet. With the introduction of Everolimus a 
further dosage reduction of CsA without losing effectiveness was possible [41, 42].  
Co-administration with CsA will increase serum levels of HMG-CoA reductase-inhibitors, 
strong inhibitors of CYP450-3A4 significantly increase the blood concentrations of CsA. 
Sulfonamides, rifampin and carbamacepine reduce CsA concentrations.  
3.3.2 Tacrolimus 
Tacrolimus (TAC) blocks the CN by forming a complex with the FK506 binding protein 
resulting in the suppression of T-lymphocyte activation and cytokine production (IL2, 3 , 
4, Interferon and tumor necrosis factor [TNF]). The structure of the macrolide antibiotic 
isolated from Streptomyces tsukubaensis is more similar to Rapamycin than to CsA. TAC 
was described seven years after the introduction of CsA [10] and found to be 100 times 
more potent [43]. It was first clinical used in 10 HTx recipients at the University of 
Pittsburgh in combination with steroids [44, 45]. When given per oral its absorption half-
life is about 5 to 6 hours and the bioavailability is about 20%, depending on the intake of 
food (fat food reduces the bioavailability, grapefruit juice increases the blood 
concentration); it is mainly absorbed in the duodenum and jejunum, far less in the ileum 
and colon. 75 – 99% bind to proteins and the elimination half-life is 11.7 hours. Its 
bioavailability is higher in patients with impaired liver function. TAC has a large inter- 
and intraindividual variation in the pharmacokinetics. Extraction is mainly through the 
stool and it can not be removed by dialysis. Similar to CsA TAC should be given in two 
divided dose every 12 hours starting orally with 0.1 to 0.3 mg/kg/day, intravenously 
0.01-0.03 mg/kg/day. Intravenously dosage in pediatric HTx might be raised up to 0.03 to 
0.05 mg/kg/day.  
Monitoring of the trough level is commercially done by an enzyme-linked immunosorbent 
assay (ELISA) or microparticulate enzyme immunoassay. Drug interactions are similar to 
CsA (inhibitor or inducers of P4503A4 may alter TAC level).   
TAC seems to reduce the numbers of rejection episodes compared to CsA; in 1992 an 
actuarial freedom from rejection in the TAC group at 90 days after HTx of 41% and 28% of 
recurrent rejection was reported [44]. Especially in children TAC is increasingly used [46]. 
Until recently TAC was marked as Prograf (Astellas Pharma US, Inc., Deerfield, IL) and had 
to be taken twice a day similar to CsA (Sandimune Neoral, Novartis Pharmaceuticals, Basel, 
Switzerland); now a retard drug was released named Advagraf (Astellas Pharma US, Inc., 
Deerfield, IL), which may be taken just once a day. It was studied in renal and liver 
transplant patients; approval for HTx is investigated.   
Even if very close related to CsA there are clinical relevant differences especially 
regarding side effects of the drug. TAC has a higher incidence of de-novo diabetes 
mellitus, a higher rate of anaemia and is increasing the tonus of the muscle. CsA on the 
other side leads to gingival hyperplasia, arterial hypertension, hirsuitsm, and increases 
liver laboratory values.  
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3.4 Purine synthesis inhibitors  
Purine synthesis inhibitors (also called Antimetabolites) can halt cell growth and cell 
division either in a very unselective way (Azathiporine, [AzA]) or a more specific way 
(Mycophenolate Mofetil, Enteric-coated mycophenolate mofetil). Since the beginning of 
modern transplantation medicine purine synthesis inhibitors (AzA) have been part of the IS 
protocol. Between 2000 and 2009 the reported use of purine synthesis inhibitors to the 
international registry for heart and lung transplantation (International Society for Heart and 
Lung Transplantation, ISHLT) as maintenance therapy in HTx recipients was over 85% [12].  
3.4.1 Azathioprine 
The pro-drug of 6-Mercaptopurin, a thiopurin substance, called Azathioprine (AzA) is a 
purine analogue IS drug which has antiproliverative effects especially on fast growing cells; 
i.e. T-cells and B-cells. AzA is metabolized to 6-Mercaptopurin which is less effective [47, 
48]. AzA blocks the mitosis of cells resulting in an inhibition of proliferation of activated T 
and B lymphocytes and it seems that AzA is blocking the production of IL2 too. 
Nevertheless its complete mechanism of action is still not fully understood. The 
antiprolivaertive effect is not limited to T and B cells but also on bone marrow, hepatic or 
other cells. This leads to its severe side effects: bone marrow depression resulting in 
leucopenia and thrombocytopenia and its hepatotoxic side effects. Other side effects like 
nausea, vomiting or diarrhoea have been reported mainly at higher doses. Long term 
treatment might be associated with acute pancreatitis. 
AzA was one of the first drugs used to prevent allograft rejection and its first human use in 
HTx was reported by the Stanford group [49]. The Standford protocol used AzA 1.5-2.5 
mg/kg per day combined with corticosteroids. Today starting dosage recommendations is 
once a day 3 to 5 mg/kg orally or i.v. and may be reduced to 1 to 3mg/kg as maintenance 
therapy.  
Its peak plasma concentration is reached within 1 to 2 hours after oral intake and its plasma 
half-life time is 3 to 6 hours. AzA is eliminated mainly by the kidney.  
One of the weak points of AzA treatment is the unspecific monitoring. Daily dosage 
administration is still adapted depending on the toxic side effects trying to target the white 
blood cell count between 4000mm3 and 6000mm3. Lately there are reports of monitoring 
AzA treatment by blood concentrations of 6-thioguanin [50]. When AzA is combined with 
allopurinol the dose should be reduced to 75% to avoid severe pancytopenia as allopurinol 
affects the metabolism of 6-Mercaptopurine. AzA may reduce the anticoagulant effect of 
Warfarin [51]. 
AzA had a major positive impact on post-transplant outcome but due to its unspecific way 
of action, severe side effects and the disadvantage of specific monitoring AzA was replaced 
in many IS protocols. On the other hand it is increasingly used in evolving countries due to 
its lower costs. 
3.4.2 Mycophenolic acid 
Mycophenolic acid (MPA) is the activated IS species of mycophenolate mofetil (MMF). MPA is 
derived from the fungus Penicillium stoloniferum and was marked as MMF. To improve its 
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bioavailability mycophenolate sodium was developed (see 3.4.2.1). MMF is a dehydrogenase 
controlling the synthesis rate of guanine monophosphate resulting in an inhibition of 
purines. Compared to AzA it specifically suppresses proliferation of T and B lymphocytes 
without severe bone marrow depression. In large multicentre trails the superiority of MMF 
over AZA was reported resulting in a progressively replacement of AzA by MMF 
[2,52,53,54]. 
Following oral administration it is rapidly metabolised 100% to MPA in the intestinal tract 
and the liver. No plasma MMF concentration will be measured in the blood, only MPA. 
MPA is bound 97% to albumin and metabolized in the liver and intestinal tract to a stable 
phenolic glucuronide (MPAG) which is not pharmacologically active. The maximum plasma 
concentration of MPA is reached about 1 hour after oral intake and its half-life time is 
around 16 hours (the same is true for MPAG). Over 90% of MPA is extracted by the kidney 
but MPAG is extracted by the bile. MPAG enters the enterohepatic cycling process; it is 
metabolised in the intestinal tract back to MPA and reabsorbed. This leads to a second peak 
in the plasma concentration after 6 to 12 hours of intake. No dosage adjustment in patient 
with renal impairment or haemodialysis is needed. In patients with a reduced glomerular 
filtration rate (GFR) a 3-to 6-fold higher MPAG area under the curve values were reported 
[55, 56]. In combination with TAC a 50% lower dose of MMF compared to a combination 
with CsA is recommended as CsA inhibits the hepatic extraction of MPAG leading to a 
reduced rate of enterohepatic recirculation. . MPA/MPAG can not be removed by 
hemodialysis. Side effects of MMF are vomiting, diarrhoea and other gastrointestinal side 
effects [57]. Diabetes and necrosis of bones have been related to MMF. A study were MMF 
was tested in pediatric HTx recipients showed that genetic polymorphism can directly 
Influence adverse events of MMF [58]. 
Initial trials using MMF used standard dosage of 1g in combination with CsA and did not 
use therapeutic drug monitoring; today dosage recommendation is 1g to 1.5 g twice a day 
orally or i.v. but when given i.v. dosage shoulkd be given at least over two hours.   
Due to the complex pharmacokinetics of MPA and not adequately reflected MPA trough 
concentrations when combined with TAC, drug level measurement of MPA is still not 
widely common. HPLC with ultraviolet detection and mass spectrometric may be used to 
measure free MPA concentrations. Some centres describe the use of an enzyme-multiplied 
immunoassay technique. Simultaneouse application of acyclovir, ganciclovir and high doses 
of salicylates are enhancing plasma concentrations of MPAG; antacids, colestyramin and 
CsA are lowering it. To reduce the gastrointestinal side effects of MMF it was coated (see 
3.4.2.1). 
3.4.2.1 Enteric-coated Mycophenolate sodium  
Enteric-coated Mycophenolate sodiumfortic (EC-MPS) is an enterie formulation of 
mycophenolate sodium (a prodrug of MPA). MPA reversible inhibits the inosine 
monophosphate dehydrogenase and the pathway of guanosine nucleotide synthesis which 
affects B and T lymphocytes whereas other cell types can utilize salvage pathyways for 
purine synthesis. The coating of mycophenolate sodium should reduce the gastrointestinal 
side effects [59]. In renal transplant recipients a dosage of 720 mg EC-MPS twice a day was 
therapeutically equivalent to MMF 1000 mg twice a day with comparable safety profile [60]. 
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Dosage recommendation in HTx recipients is 720mg twice a day either orally or 
intravenously. Optimal measurement of EC-MPS plasma concentration due to its delay in 
reaching maximal blood concentrations compared to MMF, is yet not clarify (C0, C2, C4, 
C6).  
3.5 Proliferation signal inhibitors 
Proliferation signal Inhibitors (PSI) (also named mammalian target of rapamycin (mTOR) 
inhibitors) include two important drugs currently available for organ transplantation: 
Rapamycin (Rapa) or Sirolimus (SRL) and Everolimus (EvE). Four decades ago Rapa was 
extracted and its antifungal effects reported [61]. Intensive research resulted in the discovery 
of the target of rapamycin named mTOR. mTOR is a serine-threonine kinase which is a 
transducer of information from growth factors and energy sensors within the cell. Both 
drugs form a complex with the intracellular binding protein FKBP-12, (similar to FK 506) 
but contrarily to TAC the PSIs inhibit the activity of mTOR. This leads to an arrest of a cell 
cycle in the mid-to-late G1 phase [61, 62]. While FK 506 is suppressing lymphokine 
production and blocking activation of T-cells, PSIs inhibit cells proliferation by impairing 
their response to growth-promoting lymphokines [63, 64]. They are also used in other areas 
of medicine like oncology or interventional cardiology (drug eluting stents).  
3.5.1 Rapamycin 
Rapamycin (Rapa) is a macrocyclic lactone with antifungal, antibiotic and IS properties. It 
was discovered in 1965, extracted out of soil taken from Rapa Nui in New Zeeland [65]. Its 
IS effects were discovered in the 1990s [61]. During the approval studies for Rapa the anti-
tumor effects of Rapa and its analogues like EvE were found introducing them in oncology 
and for the prevention of restenosis after percutaneous coronary angioplasty. 
Rapa has structural similarities to FK 506 binding protein but it forms complex with FKBP12 
which results in an inhibitor of the mTOR [66]. This leads to suppression of T and B cells 
and decreases the population of dentritic cells who present antigen to T cells during 
activation [67].  
The bioavailability of Rapa is 20% and decreases with food rich in fats (see 3.5.2); 92% of Rapa 
binds to albumin, is metabolism extensively in intestinal wall via p-glycoprotein and in the 
liver by CYP3A4. Seven major metabolites are known but 90% of the IS activity is done by 
Rapa; close to 90% is eliminated by the liver only 2% by the kidney. In contrast to EvE half-life 
time of Rapa is about 62 hours ± 16 hours allowing one single daily dose.  
A loading dose for Rapa on the first post-transplantation day is recommended; in renal 
transplantation the loading dose should be 3 times the estimated maintenance dose 
(normally 2mg), in HTx recipients 15mg are given followed by a maintenance dose of 5mg 
and further guided by trough levels. The total dosage must no exceed 40mg per day; if a 
higher dose is needed it should be divided over a period of 2 days. In children with a body 
weight below 40 kg initially a loading dose of 3mg/m2 and a maintenance dose of 1mg/m2 
daily is recommended. If CNI therapy is reduced, Rapa dosage should be increased 
according to the targeted trough levels. In patient with severe hepatic impairment Rapa 
dosage should be reduced.  
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Routine clinical measurement is done with chromatographic methods. Major side effects of 
Rapa are swelling in different tissues, prolonging healing of wounds, increasing cholesterol 
and triglyceride levels, proteinuria as well as blood pressure. Rapa induced interstitial lung 
disease like pneumonitis have been observed [68-70]. When combined with CNIs, CNIs 
dosage reduction is necessary otherwise worsening renal function will develop. Rapa 
recommended blood trough levels in combination with CNIs is between 4 to 12 ng/ml, 
without CsA a four times higher Rapa dosage might be needed (CsA/CNIs suppress the 
metebolizion of Rapa), the recommended blood trough levels is increased between 12 to 
20 Ng/ml depending on the time after transplantation. This is also the reason why Rapa 
intake when combined with CNIs is recommended four hours after CNI administration. 
Otherwise Rapa enhance the toxic effect of CNIs with an increased risk of CNI induced 
hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and thrombotic 
microangiogiopathy. Drugs inducing CYP3A4 (Rifampicin) will decrease, strong inhibitors 
(Macrolides, Ketoconazole, Itraconazole) will increase Rapa blood levels. Similarly to CNIs 
grapefruit juice increases plasma concentration of Rapa. According to the last ISHLT report 
Rapa is currently used up to 20 % of HTx recipients [12]. 
3.5.2 Everolimus 
Everolimus (EvE) is an analogue of Rapa and differs only by one extra hydroxyethyl group 
at position 40; still this leads to some differences. EvE blocks growth factor-mediated 
proliferation of cells including vascular smooth muscle cell through a CA2+ independent 
signal [71]. Following oral intake EvE is rapidly absorbed and reaches its maximal blood 
concentrations after 1 to 2 hours. The oral bioavailability is approximately 30% [72-75] and it 
is altered by food; a high-fat meal is slowing down the absorption of EvE. It is 
recommended that EvE is taken constantly either with or without food. EvE undergoes 
major metabolism with none of the metabolites reaching significantly IS activity. Its half-life 
time is 28 hours and compared to Rapa (62 hours) much shorter. Initial dose may be 0.75 mg 
twice a day, no loading dose is necessary.  
EvE has a more rapid time to steady state compared to Rapa (4 versus 6 days). EvE binds to 
plasma proteins about 75% to 80% and is mainly eliminated in the liver, only 5% are 
extracted across the kidney. In patient with severe hepatic impairment EvE dosage should 
be reduced. PSIs and CNIs are metabolised by cytochrome P4503A4 (CYP3A4) isoenzyme 
leading to reduced clearance of EvE when CNI is given. Pre-clinical research reported of no 
nephrotoxicity of EvE [76] but when it was first clinical used combined with full dose CsA it 
showed worsening renal function [77, 78]. For that reason FDA approval was refused, but 
the European Medicine Agency (EMEA) approved EvE for further studies. In a prospective 
multicentre study the possibility of dose reduction of CsA combined with EvE resulted in 
stable renal function without loss of efficacy [79]. Further trials confirmed this [41, 42, 80]. 
Besides this interaction drugs who strong induce CYP3A4 will decrease, strong inhibitors 
will increase EvE blood levels. Reported EvE blood trough levels are within 3 to 8 ng/ml. 
Drug monitoring is done by HPLC coupled with mass spectrometry and an immunoassay is 
being developed. EvE showed to have antiproliferative effects delaying the onset of cardiac 
transplant vasculopathy and reducing the rate of CMV infections [77, 81]; it is increasingly 
used, up to 2.6 % in HTx recipients in the years 2008 and 2009 [12]. Due to the favourable 
effects it may be used in children and is currently investigated (RAD 2313). 
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3.6 Immunosuppressive regimes 
At the beginning little was know about interaction, side-effects and combination of IS drugs. 
Nowadays with many different IS drugs acting at different receptors and stages of the 
immune system more effective and less toxic regimes may be used.  
It was revealed that the combination of different acting IS drugs with adjusted dosage 
enhance their effectiveness and reduce toxicity. To avoid nephrotoxic side effects of CNIs 
and to achieve a high IS, over 50% of the centres reporting to the ISHLT are using an 
induction therapy (20% using polyclonal antibodies, 30% use IL2 receptor antibodies) [12]. 
Conventionally for maintenance therapy patients are treated with a triple drug regimens, 
consisting of a CNI (CyC, TAC), antiproliferative agent (AzA, MMF) and corticosteroids. 
Shortly after the introduction of CsA in 1980 Griffith and colleagues used CsA in 
combination with low-dose steroids in HTx recipients, tapering steroids from 200mg per 
day to 15 mg per day similar to the regime used by Starzel in renal and liver transplant 
recipients [82-84]. Combining CsA, AzA and Cortocosteroides, commonly called triple-drug 
immunsupression, evolved and showed improved survival for short, medium and long 
term follow-up [85, 86]. It increased 1 years survival after HTx from 60% to 80% and became 
the standard regime not only in the US but also in European countries over the next 30 years 
[87, 88]. The triple-drug protocol, even if modified (many centres skipping corticosteroids 
after a certain time) is still used around the globe. Adding a forth drug to the regime has 
been reported but became not standard [19, 89]. 
Still due to the well know side effects of IS, associated with a significant morbidity, 
discussion about reducing IS will continue. Reduce IS therapy with a mono or dual drug 
regimes are investigated. Recently a retrospective study involving 150 patients within 28 
days after HTx maintaining recipients only on monotherapy with TAC has been published 
[90]. One has to notice that in IS monotherapy compliance is paramount and could result in 
a disastrous outcome. The conviction of currently experts in the field of IS is, that today’s 
“standard” immunosuppression may be replaced by IS individualized for each patient on 
the basis of genomic profile, baseline risks for rejection and infection, and perhaps serial 
assessments of immune response after transplantation [91]. 
4. Immunosuppression for acute rejection  
Different principles of IS treatment after organ transplantation have been established over 
time. After HTx numbers of rejection episodes and immune reactivity are highest within the 
first 3-6 months. Therefore one of the principles is to use the highest intensity of IS 
immediately after surgery and decrease it over the first year (Induction therapy (see 3.1), 
corticosteroid weaning (see 4.1.2); lowering blood concentrations of IS agents). The second 
principle is to rather admit more IS drugs with non-overlapping toxic side effects at a low 
dose rather than a higher and more toxic dose of a single drug. Therefore monitoring of the 
IS drug trough levels is of great interest; special caution must be paid to interaction of the 
drugs (lowering or increasing the blood levels) or i.e. diarrhea when orally taken. The goal is 
to avoid over-immunosuppression, which leads to infection and malignancy. This on the 
other hand may lead to late acute rejection episodes even if it is rare [92]. Corner stone of the 
treatment are corticosteroids, both oral or intravenous, ATG (see 3.1 Polyclonal Antibodies), 
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IL-2 receptor blockers (see 3.2 Interleukin 2 receptor antibodies) or murine monoclonal 
antibody (see 4.2). The type of treatment depends on clinical status of the recipients (if the 
rejection is hemodynamic compromising [reduced cardiac output, decreased pulmonary 
artery saturation, elevated wedge pressure, reduced cardiac index]) the histology degree 
and severity of the rejection. Moderate to severe rejection episodes need therapy: 
intravenous corticosteroids for three to five days, intensify oral maintenance IS therapy and 
eventually change to another protocol; if there are recurrent rejection episodes TAC or EvE 
may be considered. In patients with hemodynamic impairment additionally polyclonal or 
monoclonal antibodies or plasmapheresis should be kept in mind. 
4.1 Corticosteroids 
Corticosteroids inhibit the synthesis of cytokines, but the exact mechanism of action in 
solving acute rejection is not jet completely understood. Steroids suppress besides i.e. IL-6, 
interferon gamma, TNF, the production of IL-1 resulting in a diminished production of IL-2 
by activated T cells. In animal models it was reported that steroids induce lymphocytolysis 
which was not proved in humans. Synthetic pharmaceutical drugs with corticosteroid-like 
effect are used in a variety of treatments. Prednisone is the most used synthetic steroid and 
is five times more potent compared to cortisol. Its bioavailability is 70% when orally taken 
and it is metabolised in the liver. Natural steroid hormones have a very short half-life time, 
synthetic steroids like prednisone have a half-life time of 1 hour. The side effects of long-
term corticosteroids are commonly known; dosage reduction below the cushing threshold or 
even weaning them off are valid options. Nevertheless for acute rejection episodes 
intravenously high dose corticosteroid treatment is still necessary and effective. After 
solving the acute phase of the rejection episode orally corticosteroids should be introduced 
to treatment for at least some time or if already part of the maintenance IS protocol its 
dosage should be increased. 
4.1.2 Corticodsteroid weaning 
Over 85% of the centres reporting to the ISHLT are currently using corticosteroids within 
the first year after HTx, after 5 years about 50% are still using corticosteroids [12, 46]. The 
negative side effects of steroids are well known such as i.e. weight gain, glucose intolerance, 
dyslipidemia, osteoporosis, or cartaract. Most of the rejection episodes are within the first 
year after HTx and most of the steroids can be taken off over a course of a few months. The 
rationale for diminishing the overall use of corticosteroids is the availability of new IS 
agents acting more selective compared to synthetic corticosteroids. Numerous protocols 
were established, most of them use a high dosage of corticosteroids intra-operative (when 
starting reperfusion) and within the first days (as part of an induction therapy). When oral 
dosage is given different possibilities are available such as i.e. fixed dose of 15 mg per day or 
prednisolon 0.05 to 2mg/kg divided by one to four doses per day. After weeks of months 
the dose is reduced achieving a dose below the cushing threshold. Some study groups 
report to take off corticosteroids as early as 8 weeks after HTx [90] or over a course for 
several months following a simple weaning protocol guided by daily cortisol measurments 
to avoid onset of adrenal insufficiency (level > 8 µg/dl continue to wean, otherwise continue 
steroid therapy) (Baran DA. A prospective trial of steroid discontinuation in stable heart 
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transplant patients as guided by serum cortisol measurement. International Society for 
Heart and Lung Transplantation 2009, Abstract 431). Other weaning protocols decrese the 
daily prednisone dosage by 1mg each month starting at month 6 post HTx [93]. 
The question why long-term use of corticosteroids is still that present may have several 
reasons i.e. avoiding adrenal insufficiency or other potential effects when treatment is 
stopped but also the ‘heritage’ of this therapy as steroids once were nearly the only 
immunosuppressant choice for transplant recipients. 
4.2 Monoclonal muromonab CD3 antibody  
Muromonab-CD3 (brand name: OKT3) is a monoclonal antibody against CD3 antigen 
resulting in an inhibition of T-cell function by down regulation of CD3 positive cells. It was 
the first monoclonal antibody to be approved for clinical use in humans. Similar to 
polyclonal antibodies its way of administration is only intravenously. Recommended 
dosage is 5 mg per day, in pediatric patients (< 30kg body weight) initial dosage may be 
lowered to 2.5mg per day. The human body will produce human anti-mice antibodies, as 
OKT3 is like a mice-antibody explaining the loss of effectivity if given repeatedly. Toxic side 
effects besides the well know from all IS agents (higher infection rate higher rate of 
lymphoproliferative disorders) have been reported: cytokine-mediated first-dose reaction, 
pulmonary edema, aseptic meningitis, haemolytic-uremic syndrome. The first-dose reaction 
may include fever, rigors, nausea, vomiting, and diarrhea which will decrease with repeated 
exposure. Nevertheless steroids, antihistamines and antipyretics should be given along with 
OKT3 to minimize these side effects. It takes about a week after ending the OKT3 treatment 
until the T cell function returns to normal.  
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